



Haegarda® (C1 esterase inhibitor [human]) – Expanded indication

- On September 28, 2020, [CSL Behring announced](#) the FDA approval of [Haegarda \(C1 esterase inhibitor \[human\]\)](#), for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.
 - Haegarda was previously approved for this indication in adolescents and adults.
- The effectiveness of Haegarda for routine prophylaxis of HAE attacks was evaluated in a subgroup of nine patients 8 to < 17 years of age. Results of subgroup analysis by age were consistent with overall study results.
- The recommended dose of Haegarda for all patients is 60 IU per kg body weight by subcutaneous injection twice weekly (every 3 or 4 days).
 - Haegarda is intended for self (or caregiver)-administration after reconstitution. The patient or caregiver should be trained on how to administer Haegarda.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.